06.01.11
Evans Analytical Group, Inc. (EAG) has acquired Chemir Analytical Services and its affiliates, CAS-MI Laboratories and Cyanta Analytical Services. Cyanta will be renamed EAG Life Sciences to reflect its planned expansion of service. CAS-MI and Chemir will continue to operate under their current names, and all three laboratories will continue to operate at their respective facilities.
“With this acquisition we are excited that EAG can deliver our elite services to customers across a broader range of analytical, test and development offerings,” said Harry Davoody, CEO. “The combination of our companies and integrated scope of services means EAG is a stronger partner for our clients, enabling them to more effectively achieve their time to market our solutions or goals.”
EAG believes that the new acquisition will allow them to serve the industry specific needs of a diverse client base, including device and pharmaceutical companies that require FDA testing beyond materials characterization and clients seeking to develop novel coating technologies beyond surface analysis investigations. The addition also gives clients greater access to analytical capabilities.
“Chemir is pleased to become part of an organization as solid as EAG,” David W. Riggs, president of Chemir said. “Over the past year and a half we have experienced our share of hurdles and with EAG as our new owner we have the financial resources and stability our clients deserve.”
Riggs is also confident that EAG’s global reach will significantly benefit Chemir’s growth.
“Until now, Chemir has been primarily focused on U.S. clients,” he said. “We believe this acquisition will greatly enhance our failure analysis and investigational capabilities due to EAG’s extensive knowledge and instrumentation related to materials characterization and surface analysis.”
EAG is primarily owned by Odyssey Investment Partners, LLC, a private equity firm that makes majority, control investments mainly in established middle-market industrial manufacturing and business services companies in a variety of industries. EAG is headquartered in Sunnyvale, Calif. Odyssey Investment Partners has offices in New York, N.Y., and Los Angeles, Calif.
“With this acquisition we are excited that EAG can deliver our elite services to customers across a broader range of analytical, test and development offerings,” said Harry Davoody, CEO. “The combination of our companies and integrated scope of services means EAG is a stronger partner for our clients, enabling them to more effectively achieve their time to market our solutions or goals.”
EAG believes that the new acquisition will allow them to serve the industry specific needs of a diverse client base, including device and pharmaceutical companies that require FDA testing beyond materials characterization and clients seeking to develop novel coating technologies beyond surface analysis investigations. The addition also gives clients greater access to analytical capabilities.
“Chemir is pleased to become part of an organization as solid as EAG,” David W. Riggs, president of Chemir said. “Over the past year and a half we have experienced our share of hurdles and with EAG as our new owner we have the financial resources and stability our clients deserve.”
Riggs is also confident that EAG’s global reach will significantly benefit Chemir’s growth.
“Until now, Chemir has been primarily focused on U.S. clients,” he said. “We believe this acquisition will greatly enhance our failure analysis and investigational capabilities due to EAG’s extensive knowledge and instrumentation related to materials characterization and surface analysis.”
EAG is primarily owned by Odyssey Investment Partners, LLC, a private equity firm that makes majority, control investments mainly in established middle-market industrial manufacturing and business services companies in a variety of industries. EAG is headquartered in Sunnyvale, Calif. Odyssey Investment Partners has offices in New York, N.Y., and Los Angeles, Calif.